Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SF1126 in Recurrent or Progressive SCCHN with PI3K Pathway Mutations
NCT02644122Phase 2Terminated
- Start
- Nov 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of SF1126 in squamous cell carcinoma of the head and neck (HNSCC). Started Nov 2016; status: terminated.
02
Drugs
SF1126
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02644122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644122.